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Introduction
Although magnetic resonance cholangiopancreato-
graphy provides similar images as endoscopic retrograde
cholangiopancreatography (ERCP) for the diagnosis of
pancreatobiliary diseases,1,2 it still cannot completely re-
place ERCP in those patients who also require tissue
sampling and therapeutic interventions. However, ma-
nipulation of the ampulla of Vater is associated with
serum pancreatic enzyme elevations in up to 70% of
patients, and clinically acute pancreatitis may develop in
1–6% of patients.3–5 For those patients with severe post-
procedural pancreatitis, the mortality rate was about
13%.6,7
Several drugs have been used to prevent post-ERCP
pancreatitis, but their results are controversial. The drugs
included in recently published randomized controlled
studies were somatostatin8 and its analog—octreotide,9
steroids,9,10 nifedipine,11 interleukin-10,12 allopurinol,10
and gabexate.13 Somatostatin and gabexate showed
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some positive effect in preventing post-ERCP pancre-
atitis. However, a recent meta-analysis of the random-
ized control trials claimed that gabexate mesilate cannot
prevent pancreatic injury after ERCP.14 In Bordas et al’s
study,15 somatostatin injection at a dose of 250 μg
before cannulation was reported to be effective in re-
ducing the rate of post-procedural pancreatitis from
10% to 2.5%. The difference in frequency of pancreatitis
was more significant (18% vs. 0%) in the subgroup un-
dergoing endoscopic sphincterotomy. However, hyper-
amylasemia may occur after several hours for ERCP;
whether continuous infusion of somatostatin in this
setting has additional effect or not remains uncertain.
The aim of this study was, therefore, to investigate the
role of somatostatin (bolus with/without subsequent
continuous infusion for 12 hours) for the prevention
of complications after ERCP.
Methods
From July 1999 to September 2000, 133 patients with
benign biliary disease who received ERCP for diagnosis
or treatment were enrolled in our study. Patients with
malignant disease, other severe systemic illness, and his-
tory of gastrectomy with Billroth’s II anastomosis were
excluded.
After enrolment, patients were randomly put into
3 groups. Group A patients received somatostatin
250 μg infusion before ERCP, followed by continu-
ous infusion with somatostatin 250 μg/hour for 12
hours. Group B patients received somatostatin 250 μg
before ERCP only, with no subsequent infusion.
Group C patients did not receive any somatostatin
before or after ERCP. Local anesthesia of the pharynx
with 8% xylocaine and intramuscular injection with
hyoscine-N-butylbromide 40 mg were given as pre-
medication. Forty-five patients received a diagnostic
ERCP only, 83 patients received endoscopic sphinc-
terotomy (EST) for the treatment of common bile
duct stones, 3 patients received EST plus plastic stent
placement due to incomplete stone extraction, and 
2 patients received nasobiliary drainage for obstructive
jaundice and cholangitis.
Post-ERCP pancreatitis was defined as abdominal
pain associated with serum amylase level at least 3 times
the normal value at 24 hours or more after ERCP, re-
quiring admission or prolongation of planned admis-
sion.16 Post-procedural hyperamylasemia was defined
as serum amylase level equal to or more than 2 times
the normal value (110U/L) or higher than the baseline
serum amylase value in patients with hyperamylasemia
before ERCP.
Random number tables were used to randomize the
patients into the 3 groups. Continuous variables were
expressed as mean ± standard deviation. Student’s t test
or 1-way ANOVA was used to analyze continuous vari-
ables, while the χ2 or Fisher’s exact test was used for
categorical variables. A p value of less than 0.05 was
considered to be significant.
The Department of Education and Research of
Kaohsiung Veterans General Hospital approved this
study, and informed consent was obtained from each
patient.
Results
A total of 133 patients (group A, 44; group B, 40; group
C, 49) were enrolled in our study. The sex, age, inci-
dences of juxtapapillary diverticulum, intact gallblad-
der, and hyperamylasemia before ERCP were similar
in the 3 groups (Table 1).
There were no significant differences in bile duct and
pancreatic duct visualization, the ratio of diagnostic and
therapeutic ERCP, the procedure time, post-procedural
hyperamylasemia and pancreatitis among the 3 groups
(Table 2). The incidence of post-procedural pancreatitis
in group A was higher than in groups B and C (6.8%,
2.5% and 4.1% respectively), but there was no statisti-
cally significant difference. However, due to the more
than expected number of patients (3/44, 6.8%) who
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Table 1. Characteristics of the 3 groups of patients*
Characteristics Group A (n = 44) Group B (n = 40) Group C (n = 49) p
Sex (M/F) 26/18 20/20 26/23 0.69
Age (yr) 59.7 ± 15.5 62.9 ± 14.5 65.4 ± 13.7 0.18
Juxtapapillary diverticulum 15 (34) 15 (38) 13 (27) 0.52
Intact gallbladder 34 29 39 0.38
With stone 18 15 13
Hyperamylasemia before ERCP 8 (18) 6 (15) 11 (22) 0.67
*Data presented as n or mean ± standard deviation or n (%). ERCP = endoscopic retrograde cholangiopancreatography.
suffered from post-ERCP pancreatitis in group A
(bolus +continuous infusion of somatostatin), the study
was terminated early in order to prevent morbidity
among the patients.
Furthermore, there was no difference in post-
procedural hyperamylasemia between diagnostic and
therapeutic ERCP within the same group.
For patients with visualization of pancreatic duct,
the incidences of post-procedural hyperamylasemia were
higher than in those without visualization of pancre-
atic duct in all 3 groups; it was statistically significant
in groups A and C (p = 0.03 and 0.002, respectively)
(Table 3).
Six patients met the criteria for post-ERCP pan-
creatitis; all of them belonged to the group of pancre-
atic duct visualization (p = 0.02). Fortunately, they all
recovered after conservative treatment. In addition,
25 patients received ERCP for suspected gallstone
pancreatitis; EST was performed in 13 of them, and
the procedures were smooth. Twelve patients had nor-
mal cholangiogram, probably due to stone pass-out, and
received no treatment. One patient developed acute
pancreatitis again after ERCP, which was resolved by
conservative treatment.
Discussion
It is generally believed that acute pancreatitis is one of
the most frequent and serious complications of ERCP
and EST. The risk of pancreatitis cannot be eliminated,
and the search for suitable drugs to prevent this compli-
cation remains of considerable importance. The possi-
ble reasons for why somatostatin can prevent acute
pancreatitis are related to the effects of inhibiting pan-
creatic exocrine secretion by suppressing the release of
secretin and cholecystokinin17 and reducing the pressure
in the intrapancreatic ducts by inhibiting the motility
of the sphincter of Oddi.18 In our previous study, so-
matostatin reduced the basal pressure of the sphincter
of Oddi significantly in more than 93% of patients with
acute non-biliary pancreatitis.19
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Table 2. Results of endoscopic retrograde cholangiopancreatography in the 3 groups*
Group A (n = 44) Group B (n = 40) Group C (n = 49) p
Visualization of bile duct 44 (34) 38 (30) 47 (36) 0.35
Visualization of pancreatic duct 26 (59) 18 (45) 26 (53) 0.43
Diagnostic/therapeutic 12/32 14/26 19/30 0.50
Duration of procedure (min) 32.1 ± 22.3 31.7 ± 16.4 32.8 ± 17.7 0.96
Post-procedural hyperamylasemia† 13 (29.5) 13 (32.5) 20 (40.8) 0.49
Diagnostic 1 (8) 3 (21) 9 (47) 0.05
Therapeutic 12 (38) 10 (38) 11 (37) 0.99
Pancreatitis 3 (6.8) 1 (2.5) 2 (4.1) 0.63
Diagnostic 1 0 1 0.57
Therapeutic 2 1 1 0.84
*Data presented as n (%) or n or mean ± standard deviation; †serum amylase ≥ 220 U/L.
Table 3. Post-procedural hyperamylasemia and pancreatitis in patients with and without visualization of the pancreatic duct
Pancreatic duct
p
Visualization Non-visualization
Hyperamylasemia
Group A 11/26 2/18 0.03
Group B 7/18 6/22 0.44
Group C 16/26 4/23 0.002
Total 34/70 12/63 < 0.001
Pancreatitis
Group A 3/26 0/18 0.14
Group B 1/18 0/22 0.26
Group C 2/26 0/23 0.17
Total 6/70 0/63 0.02
According to the results of Testoni et al’s study,20
serum amylase could attain peak level at 8 hours after
the ERCP procedures. However, 46.9% (192/409)
of patients still had post-procedural hyperamylasemia
(> 220 U/L) after 24 hours. Among them, 6.3% had
more than 5 times the upper limit of normal, and 73%
of these patients were considered to have some degree
of pancreatic reaction, although typical pictures of pan-
creatitis on computed tomography were documented
in only 7 patients (36.8%), which was equal to 1.7% of
all patients under investigation. The reason for record-
ing the 24-hour amylase level in our study was based
on the more significant clinical value of it. The reduction
of post-ERCP complications seemed more consistent
for somatostatin given by bolus injection in the recent
meta-analysis studies, while controversy exists regard-
ing the effect of long duration of infusion of the drug.
Andriulli et al claimed that short- or long-term infu-
sion of somatostatin was ineffective in reducing post-
ERCP pancreatitis, although bolus injection of it could
have a beneficial effect on post-procedural hyperamy-
lasemia.21 On the other hand, Rudin et al believed that
somatostatin administrated as a bolus is the optimal
choice for the prophylaxis of post-ERCP complications
with regard to the efficacy, ease of administration and
applicability to daily practice.22 In our study, however,
there was no significant difference among the groups
who received bolus injection with or without continuous
infusion of somatostatin and the control, with respect
to the reduction of post-procedural hyperamylasemia
and pancreatitis. The higher post-procedural hyperamy-
lasemia in group C was probably due to some effect of
somatostatin in the treatment groups. Also, the inci-
dence of post-ERCP pancreatitis was only 4% in the
control group.
There are possible method-related risk factors for
the occurrence of post-ERCP acute pancreatitis: repeat
instrumentation of the pancreatic duct due to difficulty
in selective cannulation of the bile duct, hydrostatic
injury from over-injection, acinarization of the gland,
high osmolality of conventional ionic contrast media,
biliary obstruction, infection, and normal instead of
diseased pancreas.16,23 In our study, patients with visu-
alization of the pancreatic duct had higher incidence
of hyperamylasemia and post-ERCP pancreatitis, so, we
took several measures in order to lower the severity of
the possible pancreatitis after the procedures, including:
avoiding unnecessary ERCP examinations, diluting the
contrast medium, avoiding over-injection of contrast
and acinarization by means of changing the patients’
posture to obtain the opacification of the pancreatic tail,
doing EST and draining the bile duct for cases with signs
of biliary obstruction. As a result, even though we had
a similar rate of hyperamylasemia in our cases compared
to the other reports, our patients showed relatively minor
symptoms.
Acute pancreatitis was once a contraindication for
ERCP. However, carefully selected patients with gall-
stone pancreatitis have been treated successfully using
ERCP procedures. Of 25 patients diagnosed as hav-
ing gallstone pancreatitis before the procedure, 24
did not have deterioration of pancreatitis after ERCP.
It clearly demonstrated the safety of ERCP for this
group of patients.
On the other hand, all patients who suffered from
post-ERCP pancreatitis also had pancreatic duct visu-
alization during the procedure. This implies that the
best way to avoid post-ERCP pancreatitis is to selec-
tively cannulate the bile duct in simple biliary disease
and avoid repeated cannulation and excessive contrast
injection in cases of strong indications for visualiza-
tion of the pancreatic duct.
The drawback of this study is the possible β-error
resulting from the small number in the study group.
However, the incidence of post-ERCP pancreatitis
was low and mild in our patients, and the incidence of
acute pancreatitis in the group with continuous infu-
sion was higher than in the other groups (6.8% vs.
2.5% and 4.1%, respectively).
In conclusion, continuous infusion of somato-
statin after ERCP does not seem to be helpful in the
prevention of pancreatic complications after ERCP.
Pancreatic duct visualization is the risk factor for pan-
creatic complications.
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